Tags

Type your tag names separated by a space and hit enter

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
Biol Psychiatry 2005; 57(6):594-608BP

Abstract

BACKGROUND

Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders.

METHODS

In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated schizophrenia patients. These data were compared with effects in healthy subjects reported elsewhere.

RESULTS

Delta-9-tetrahydrocannabinol transiently increased 1) learning and recall deficits; 2) positive, negative, and general schizophrenia symptoms; 3) perceptual alterations; 4) akathisia, rigidity, and dyskinesia; 5) deficits in vigilance; and 6) plasma prolactin and cortisol. Schizophrenia patients were more vulnerable to Delta-9-THC effects on recall relative to control subjects. There were no serious short- or long-term adverse events associated with study participation.

CONCLUSIONS

Delta-9-tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia. These data do not provide a reason to explain why schizophrenia patients use or misuse cannabis. Furthermore, Delta-9-THC might differentially affect schizophrenia patients relative to control subjects. Finally, the enhanced sensitivity to the cognitive effects of Delta-9-THC warrants further study into whether brain cannabinoid receptor dysfunction contributes to the pathophysiology of the cognitive deficits associated with schizophrenia.

Authors+Show Affiliations

Schizophrenia Biological Research Center, VA Connecticut Healthcare System, West Haven, CT 06516, USA. deepak.dsouza@yale.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15780846

Citation

D'Souza, Deepak Cyril, et al. "Delta-9-tetrahydrocannabinol Effects in Schizophrenia: Implications for Cognition, Psychosis, and Addiction." Biological Psychiatry, vol. 57, no. 6, 2005, pp. 594-608.
D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608.
D'Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., ... Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry, 57(6), pp. 594-608.
D'Souza DC, et al. Delta-9-tetrahydrocannabinol Effects in Schizophrenia: Implications for Cognition, Psychosis, and Addiction. Biol Psychiatry. 2005 Mar 15;57(6):594-608. PubMed PMID: 15780846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. AU - D'Souza,Deepak Cyril, AU - Abi-Saab,Walid Michel, AU - Madonick,Steven, AU - Forselius-Bielen,Kimberlee, AU - Doersch,Anne, AU - Braley,Gabriel, AU - Gueorguieva,Ralitza, AU - Cooper,Thomas B, AU - Krystal,John Harrison, PY - 2004/08/05/received PY - 2004/11/16/revised PY - 2004/12/03/accepted PY - 2005/3/23/pubmed PY - 2005/6/21/medline PY - 2005/3/23/entrez SP - 594 EP - 608 JF - Biological psychiatry JO - Biol. Psychiatry VL - 57 IS - 6 N2 - BACKGROUND: Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders. METHODS: In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated schizophrenia patients. These data were compared with effects in healthy subjects reported elsewhere. RESULTS: Delta-9-tetrahydrocannabinol transiently increased 1) learning and recall deficits; 2) positive, negative, and general schizophrenia symptoms; 3) perceptual alterations; 4) akathisia, rigidity, and dyskinesia; 5) deficits in vigilance; and 6) plasma prolactin and cortisol. Schizophrenia patients were more vulnerable to Delta-9-THC effects on recall relative to control subjects. There were no serious short- or long-term adverse events associated with study participation. CONCLUSIONS: Delta-9-tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia. These data do not provide a reason to explain why schizophrenia patients use or misuse cannabis. Furthermore, Delta-9-THC might differentially affect schizophrenia patients relative to control subjects. Finally, the enhanced sensitivity to the cognitive effects of Delta-9-THC warrants further study into whether brain cannabinoid receptor dysfunction contributes to the pathophysiology of the cognitive deficits associated with schizophrenia. SN - 0006-3223 UR - https://www.unboundmedicine.com/medline/citation/15780846/Delta_9_tetrahydrocannabinol_effects_in_schizophrenia:_implications_for_cognition_psychosis_and_addiction_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-3223(04)01310-1 DB - PRIME DP - Unbound Medicine ER -